Kasia Lipska News Today

"As with insulin, our patients are facing parallel challenges in accessing other new non-insulin diabetes and anti-obesity medications."

For years, Yale School of Medicine's Kasia Lipska, MD, MHS, has been advocating for affordable pricing of insulin, an essential —and sometimes lifesaving—drug

Dr. Kasia Lipska unveils the financial strains patients face in her fight for accessible diabetes and obesity treatments, urging a prescription for change.

As more people seek out weight-limiting drugs, food industry watchers do not see diets or food patterns shifting dramatically in the year ahead. However, food companies will be watching closely to position themselves moving forward.

Kasia Lipska, MD, MHS, was one of five experts invited to testify at the Senate Health, Education, Labor, and Pensions (HELP) committee hearing on December 14,

Yale School of Medicine’s Department of Internal Medicine had a banner year. The department opened new clinical facilities, debuted novel clinical programs,

Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and...

The Senate HELP committee hearing featured debates over how to reign in insulin prices and hold food companies accountable for manufacturing unhealthy products. The Senate HELP committee hearing featured debates over how to reign in insulin prices and hold food companies accountable for manufacturing unhealthy products.

Senators discussed the impact of the diabetes and obesity epidemics during a hearing on Thursday. They say the epidemics are harming millions of Americans and costing billions of dollars.

This Medical News article discusses Wegovy, Ozempic, and other GLP-1 receptor agonists used for weight management and type 2 diabetes.